Currently several studies are ongoing to evaluate the efficacy of perioperative EGFR‐targeted therapies in patients with resected or resectable NSCLC (e.g., NCT04351555 and NCT03433469; www.clinicaltrials.gov). This evidence concerns the gene EGFR and non-small cell lung carcinoma.